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Direct hemoperfusion therapy with polymyxin B
immobilized fiber cartridge (PMX-DHP) is an established
strategy in the treatment of septic shock in Japan and
parts of Western Europe. PMX-DHP is currently the subject
of a pivotal North American randomized controlled trial
(EUPHRATES) in patients with septic shock and confirmed
endotoxemia, as measured by the endotoxin activity assay.
The major mechanism of action of this therapy is the
removal of circulating endotoxin. High affinity binding of
circulating endotoxin by the PMX-DHP column may
decrease circulating endotoxin levels by up to 90% after
two standard treatments. Basic research has shown
reductions in circulating cytokine levels and in renal tubular
apoptosis. Clinical research has shown that PMX-DHP
therapy results in hemodynamic improvements,
improvements in oxygenation, renal function, and
reductions in mortality. Further research is needed to
further define additional patient populations with
endotoxemia that may benefit from PMX-DHP therapy
as well as to further elucidate dosing, timing, and
additional information on mechanisms of action. This
review will present the mechanistic rationale for this
targeted strategy of endotoxin removal using PMX-DHP
in endotoxemic septic patients, highlighting both the
specific effects of the therapy and the evidence
accumulated so far of clinical improvement following
this therapy in terms of recovery of organ function.coming many of the interference issues that exist withTargeting lipopolysaccharide in septic shock
This viewpoint discusses the proven and potential mech-
anisms of action for polymyxin B hemoperfusion (PMX-
DHP) as a biologically plausible and clinically efficacious
therapy in sepsis and endotoxemia. The role of endo-
toxin or lipopolysaccharide (LPS) in sepsis is well* Correspondence: cronco@goldnet.it
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2014established with over 10,000 publications in the medical
literature. LPS is a key component of the membrane of
Gram-negative bacteria. Structurally, its biologic activity
relates to the lipid A portion of the molecule, which is
highly conserved across most bacterial species [1]. LPS
when injected systemically in both animals and humans
in a dose-dependent fashion induces elevations in cyto-
kines, including TNF-α, IL-6, and IL-8 [2,3]. Clinical re-
sponses include pyrexia, chills, hypotension, and, at
higher doses, shock, organ failure and death [4]. Numer-
ous studies have shown elevated levels of circulating LPS
in patients with sepsis originating not only from Gram-
negative infections, but also in patients with Gram-
positive infections, and in those where cultures do not
identify a microbiologic source of sepsis [5,6]. The likely
mechanism of endotoxemia in these cases is the trans-
location of gut microbial flora secondary to intestinal hy-
poperfusion. Animal studies supporting this hypothesis
have included those that have identified high levels of
circulating LPS after supra-celiac aortic cross clamping
for aortic surgery [7,8]. Similar observations of endo-
toxemia have been noted in human cardiopulmonary
bypass, severe burn, liver transplant, and trauma pa-
tients [9,10].
The possibility to do these studies has been bolstered
by the development of the endotoxin activity assay
(EAA), which has allowed accurate measurement of
endotoxin activity levels in vivo [11]. The EAA measures
the activity of circulating bio-available lipid A, thus over-
the limulus ameobocyte lysate assay. Elevations in the
EAA correlate well with the observed clinical status of
patients. EAA levels in sepsis patients in the ICU correl-
ate with adverse outcomes, including risk of death and
duration of hospital stay [5]. It has also been demon-
strated that elevation in the EAA can provide additional
prognostic value in assessing patients with milder or
earlier forms of sepsis, in perioperative major surgery
patients, and in severe sepsis and septic shock patientstral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Time frame of events and windows of opportunity for
treatment. EAA, endotoxin activity assay.
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contemplated [12-14].
Importantly, studies have demonstrated persistent ele-
vations in LPS levels as measured by the EAA up to 3
days after initial development of severe sepsis. Further-
more, the total exposure to circulating endotoxin as
measured by the area under the curve when EAA levels
are plotted over the first 3 days of admission (endotoxin
burden) correlates with the degree of total organ failure
[15]. Organ failure is the biggest correlate to attributable
mortality in sepsis [16]. Finally, fluctuations in circulat-
ing endotoxin levels in septic patients have been shown
to be associated with adverse outcomes [15]. This has
led to the hypothesis that both the elimination of high
levels of circulating endotoxin and the blunting of the
changes in these levels over time is a potential thera-
peutic strategy in endotoxemia with associated septic
shock (Figure 1).
Polymyxin B
Polymyxin B is a cyclic cationic polypeptide antibiotic
derived from Bacillus polymyxa that has the ability to
bind and neutralize endotoxin [17]. Studies have shown
that systemic polymyxin B blunts the TNF-α response toFigure 2 Polymixin B cartridge containing polystyrenic fibers boundendotoxin [18]. Polymyxin B also blocks the formation
of LPS-LPS binding protein complexes through its high
binding affinity for the LPS molecule. Unfortunately, in-
fusion of polymyxin in humans results in nephrotoxicity
and neurotoxicity, limiting its intravenous use to salvage
therapy for Gram-negative enterobacteriaciae resistant
to other antibiotics [17]. Clinical trials of polymyxin B as
an anti-sepsis/anti-endotoxin agent bound to dextran
failed to advance through clinical trials in the 1990s,
again related to systemic toxicity [19].
Hemoperfusion with polymyxin B immobilized
cartridges
A novel therapeutic strategy whereby polymyxin B is
immobilized to a polystyrene-derived fiber in a hemo-
perfusion device that is used to remove circulating endo-
toxin was developed in Japan in the early 1990s [20]
(Figure 2). The PMX cartridge was created by covalently
immobilizing polymyxin B to polystyrene-derived fibers,
which can then be used to filter blood externally using
an extracorporeal circuit, thereby removing circulating
LPS through its adsorption to the PMX cartridge. The
surface area of the cartridge is extremely large, allowing
up to 90% of circulating endotoxin to be cleared in a
short period of time, as demonstrated by Shoji and col-
leagues [20]. Clinically, the EAA-J study confirmed that
endotoxin levels may fluctuate in the inter-treatment
period thought to be related to the movement of endo-
toxin out of other compartments (protein bound, mi-
celles, ongoing septic sources), reinforcing the potential
rationale for current practice of two treatments 24 hours
apart [21]. To date, PMX-DHP has been used in more
than 100,000 patients with a very low incidence of ad-
verse events (<1%) and high tolerability. The most com-
monly observed adverse events are thrombocytopenia,
transient hypotension and allergic reactions. These have
been logged by regulators in North America, Europe,
and Japan, as well as in the EUPHAS2 registry currently
active in Europe, and in published literature. There is noto polymixin-B.
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tion in significant quantities in treated patients.
Small randomized studies on this device have also
shown the ability of the PMX cartridge to dramatically
reduce endotoxin concentrations compared with carrier
fiber cartridges, charcoal or resin over the course of a
2-hour treatment [22]. Due to the strong binding capacity
of polymyxin B and the affinity of polymyxin B for the
highly conserved lipid A portion of LPS, the device has
also been shown to remove a large variety of the various
endotoxins produced by an array of different Gram-
negative bacteria, showing the versatility of this treatment.
Recently, Tani and colleagues [23] tested the endotoxin
adsorption capacity of the device, reporting that the PMX
cartridge is able to trap approximately 300,000 endotoxin
units in a standard 2-hour perfusion session. This corre-
lates well with the observed order of magnitude of the typ-
ical endotoxin burden during severe sepsis. Similarly, the
EAA-J trial demonstrated an average absolute 20% reduc-
tion in EAA levels (from 0.65 to 0.45) in an unselected co-
hort of septic patients who received PMX-DHP on clinical
grounds at the discretion of the treating physician, repre-
senting very roughly a 2,000 pg/ml reduction in endotoxin
levels [21].
Mechanism of action
The main mechanism of action behind PMX-DHP is the
direct adsorption of circulating LPS. At the molecular
level this relies on both the polystyrene-polymyxin B
bonding and the LPS-polymyxin B affinity (Figure 3).
The first bond is the covalent linkage of polymyxin B to
the fiber surface, thus protecting the patient from theFigure 3 Lipopolysaccharide (LPS) binds to polymixin B (PMX) with w
this type of removal from any other system. Dab, hydrophilic residues; Leu,nephrotoxic and neurotoxic effects of polymyxin B. Mo-
lecular studies on polymyxin B and LPS interaction have
determined that a stable bond is created, with hydropho-
bic interactions dominating the interaction for intermo-
lecular distances up to 1 nm, such as between the lipid
A and polymyxin B hydrophobic residues. At larger
intermolecular distances, LPS phosphate groups, with
negatives charges, interact with positively charged diami-
nobutyric acid residues of polymyxin B, giving rise to
ionic interactions [24]. The large surface area of the
PMX column exerts fluid drag but allows for a large
amount of interaction with the fiber. Fiore and col-
leagues [25] have shown that, within a wide range of wall
sheer stresses, the capability of polymyxin B to capture
endotoxin molecules extends to distances of one order
of magnitude greater than the characteristic distance of
the stable intermolecular hydrophobic bond. Therefore,
the polymyxin adsorbed to the fiber is able to capture
LPS from a threshold distance of 10 to 20 nm during the
normal blood flow of a standard treatment.
As a secondary mechanism the PMX column has also
been reported to remove inflammatory cells such as
monocytes and neutrophils [26]. While it is unlikely that
these inflammatory cells are removed through binding
with PMX directly, they may be removed by either being
physically entrapped by the fiber weave of the filter or
attaching to LPS, which in turn binds to polymyxin,
thereby using LPS as an adsorption bridge (Figure 4).
White cell count reductions have been observed clinic-
ally in some patients treated with PMX-DHP. In either
case, the removal of activated inflammatory cells can
have the secondary effect of reducing the circulatingeak ionic forces and strong hydrophobic forces. This differentiates
Leucine; MOA, methyl octanoic acid; Phe, Phenylalanine.
Figure 4 Pictorial view of activated cells adsorbed by
the fibers.
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TNF-α and IL-6. Consequently, the exaggerated systemic
immune response of patients can be reduced, preventing
or decreasing multiorgan failure.
Interestingly, PMX-DHP treatment has also been asso-
ciated with decreasing circulating apoptotic factors, such
as Fas, Fas-L, Bax, Bcl-2, and reductions in the levels of
renal tubular and glomerular cellular apoptosis, which in
turn was associated with recovery of renal tubular for-
mation, reduced inflammation and improved renal func-
tion [27]. This provides another potential mechanism
involved in the overall reduction in organ dysfunction
following PMX-DHP, including a rationale for the often
observed clinical effect on acute kidney injury.
There are other reports of PMX-DHP therapy chan-
ging levels of other measurable players in the inflamma-
tory response in sepsis. These include lipotichoeic acid,
HMGB-1, and even mediators of the inflammatory re-
sponse in amiodarone toxicity [28,29]. However, there is
little causal evidence to support a direct role for PMX in
these cases. The mechanisms for this are unclear and
may reflect pleiotropic effects of reducing endotoxin
burden.
Animal data
The first large mammal safety study of PMX was done
in 20 dogs infused with Escherichia coli in a Gram-
negative sepsis model. It demonstrated the ability of
PMX-DHP to reduce circulating endotoxin levels, im-
prove blood pressure, and reduce mortality in treated
animals [30]. Further studies in guinea pigs and sheep
have noted improved gastrointestinal perfusion and re-
ductions in clinical parameters of shock and hypoxemia
in sepsis models [31,32]. Recently, animal studies from
Japan have focused on potential new areas for clinical use




There are many published trials of small and somewhat
heterogeneous cohorts of patients mainly from Japan as
well as case reports and case series from elsewhere dem-
onstrating impressive efficacy of PMX-DHP in severe
sepsis. Studies on human subjects have been reported
since 1994 [34], with more than 120 English language
publications reporting on over 2,000 patients treated
with PMX-DHP now in the public domain. The first
multi-center trial was done by Tani and colleagues in
1998 [35], where 37 of 70 subjects with severe sepsis
were treated with PMX-DHP and the treatment group
demonstrated an 18% reduction in absolute 14-day mor-
tality compared to the control population.
Meta-analyses/systematic reviews
Recently, Zhou and collaborators [36] published a meta-
analysis of all randomized trials of blood purification
strategies in sepsis, including high volume hemofiltra-
tion, PMX-DHP, and plasma exchange. Importantly,
while they showed an overall reduction in mortality from
50.1% to 35.7% (odds ratio 0.69, 95% confidence interval
0.56 to 0.84), they highlighted that the result would no
longer be significant if the eight trials on PMX-DHP
with 457 patients were excluded, thus suggesting that
the clinical effect that drove the result of the meta-
analysis was principally due to the PMX-DHP trials.
Cruz and colleagues published an earlier systematic re-
view and meta-analysis of 28 trials where PMX-DHP
was used to treat patients with severe sepsis and septic
shock. Although there was heterogeneity amongst the
trials, which were largely done in Europe and Japan, across
a total cohort of 978 patients treated with the therapy,
improvements were noted in hemodynamics (mean arter-
ial pressure) as well as oxygenation (P/F ratio), and there
was a statistically significant improvement in risk of death
(risk ratio 0.53, 95% confidence interval 0.43 to 0.65) [37].
Nevertheless, these data need to be considered as hypoth-
esis generating, since despite the strong positive clinical
signal, the included trials are largely underpowered, un-
blinded, and have variable inclusion criteria.
Randomized controlled trials
European pilot trial
A European multicenter pilot trial was conducted by
Vincent and colleagues [38] in six academic centers in
France, Belgium, Spain, Germany, The Netherlands and
the UK. The study was powered for safety and surrogate
non-mortality endpoints. Treatment consisted of only a
single PMX cartridge, which is considered half of the
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were randomized to PMX- DHP (n = 17) or standard
care (n = 19). There was no difference in mortality, al-
though there was a statistically significant improvement
in mean arterial pressure and other hemodynamic mea-
sures as well as a reduction in the need for renal replace-
ment therapy in the treated group. From the safety
perspective, authors reported a safety profile that was fa-
vorable towards PMX-DHP versus the control population.
EUPHAS
In 2009, the Early Use of Polymyxin Hemoperfusion in
Abdominal Septic Shock (EUPHAS) trial, a randomized
unblinded study of 64 patients in 10 tertiary Italian
ICUs, demonstrated statistically significant improve-
ments in the primary endpoints of hemodynamics and
organ dysfunction. Specifically, renal function as mea-
sured by improvement of serum creatinine, diuresis, and
the renal component of the Sequential Organ Failure
Assessment score at 72 hours showed positive trends.
Also, the absolute risk of death at 28 days improved sig-
nificantly from 53% in the conventional therapy group
to 32% in the PMX-DHP treated group (P = 0.03). These
results, albeit encouraging, are considered controversial
as the trial was stopped early after an interim analysis
showed a mortality difference, which was a secondary
endpoint. In addition, the trial was not blinded. Patients
were selected for therapy based on evidence of septic
shock from an intra-abdominal source to hopefully en-
rich the patient population with likely endotoxemic pa-
tients, but the EAA was not measured. Despite these
limitations, EUPHAS may have had a comparative ad-
vantage to other sepsis trials that selected patients for
anti-endotoxin therapy regardless of source of sepsis or
measured levels of endotoxin.
Ongoing studies
EUPHAS2
EUPHAS2 is a prospective web-based registry of patients
treated with PMX-DHP designed to validate the repro-
ducibility of randomized clinical trial results and to ob-
serve the 'real world' efficacy and utility of PMX-DHP
therapy across a wider variety of patient populations
than those included in clinical trials. To date, the regis-
try has captured data on 426 treated patients. Unpub-
lished data from the registry that have been presented to
date seem to show similar benefits to those observed in
EUPHAS and other trials.
ABDO-MIX
The effects of Hemoperfusion With a Polymyxin B
Membrane in Peritonitis With Septic Shock (ABDO-
MIX; ClinicalTrials.gov NCT01222663) is a French ran-
domized, controlled, open label multi-centered studythat evaluated 28 day mortality in patients with septic
shock due to peritonitis. Eligible patients were random-
ized to standard care versus standard care plus PMX-
DHP within 36 hours of abdominal surgery to repair a
hollow viscous perforation. The trial enrolled 240 pa-
tients. Although this study has not been published, pre-
liminary results were presented at the 2014 ISICEM
conference. This study failed to show a difference in mor-
tality between the groups, but the study had a number of
potential problems that may have contributed to this ob-
servation. These include cartridge clotting and failure
rates that are dramatically higher than in other trials or
clinical experience to date suggesting technical issues in
the implementation of the therapy protocol. Also, the ob-
served composite mortality was substantially less than the
estimate included in the sample size calculation, thus de-
creasing the power of the study to detect a difference. Still,
once published, ABDO-MIX should be carefully reviewed
in the context of other previous and emerging data.
EUPHRATES
The EUPHRATES trial (Evaluating the Use of Polymyxin
B Hemoperfusion in a Randomized Controlled Trial of
Adults Treated for Endotoxemia and Septic Shock; Clin-
icalTrials.Gov NCT01046669) is a multi-centered,
blinded, randomized controlled trial of PMX-DHP in pa-
tients with septic shock and confirmed endotoxemia
using EAA greater than 0.60. The trial is being con-
ducted in 50 ICUs in the United States and Canada and
aims to enroll 360 patients, but has an adaptive design
that allows for a sample size adjustment based on a Data
and Safety Monitoring Board interim analysis. The pri-
mary endpoint for the trial is 28-day all-cause mortality.
Unique features of the trial include absence of systemic
inflammatory response syndrome criteria as a require-
ment for inclusion, use of the EAA to confirm endotoxe-
mia as a requisite for treatment, and use of a detailed
'fascade' hemoperfusion event as a blinding mechanism.
Similar to previous studies, PMX-DHP is being done in
two treatment sessions of 2 hours duration approxi-
mately 1 day apart. Patients are enrolled after persistent
septic shock despite adequate fluid resuscitation who re-
main on vaspressors for at least 2 but not more than 30
hours and have an EAA >0.60.
Conclusion
PMX-DHP is a well-tolerated and safe treatment for sep-
tic shock with a long history of clinical experience and
both clinical and basic science data to support efficacy
in endotoxemia. Its principle mechanism of action is
through the removal of circulating endotoxin, although
its effects are likely pleiotropic. In an era of numerous
failed clinical trials in sepsis, it is easy to be cynical.
However, this personalized, targeted approach to a
Ronco and Klein Critical Care Page 6 of 72014, 18:309
http://ccforum.com/content/18/3/309disease with unacceptable mortality, with a treatment
with a long history of clinical use and strong supporters
around the globe truly may represent a step forward in
improving patient care.Abbreviations
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